

Please amend the claims as shown in the listing below:

In the claims:

1. (Canceled)

2. (Previously presented) The method according to claim 17 wherein said autoimmune disease is generated by a failure in the production of IL-4 by Th2 cells.

3. (Previously presented) The method according to claim 17 wherein said autoimmune disease is generated by a failure in the production of IL-4 by T cells with sub-type HSA<sup>-</sup>, CD4<sup>-</sup>CD8<sup>-</sup> or CD4<sup>+</sup>CD8<sup>-</sup>, CD44<sup>+</sup>, TCR-αβ<sup>+</sup>, Vβ8<sup>+</sup>, NK1.1<sup>+</sup>.

4. (Previously presented) The method according to claim 17 wherein said autoimmune disease is insulin-dependent diabetes mellitus, autoimmune encephalo-myelitis, autoimmune rheumatoid arthritis, polyarthritis, autoimmune-type 2 hepatitis, autoimmune gastritis, autoimmune sclerosis, sialadenitis, adrenalitis, oophoritis, glomerulonephritis or autoimmune thyroiditis or autoimmune-type pathology from therapy associated with treating AIDS.

5. (Canceled)

6. (Previously presented) The method according to claim 17 wherein said T lymphocytes are autologous or syngeneic cells of said patient.

7. (Currently amended) A pharmaceutical composition for treating autoimmune diseases related to a failure of immunoregulation by CD4<sup>+</sup> cells or diminished production of IL-4 comprising as the active principle, autologous or syngeneic T lymphocytes selected from the group consisting of thymocytes, said lymphocytes being autologous or syngeneic to the patient for whom the pharmaceutical composition is intended, said T lymphocytes having previously been incubated in the presence of IL-7.

8 and 9. (Canceled)

10. (Previously presented) The pharmaceutical composition according to claim 7 for

treating insulin-dependent diabetes mellitus.

11. (Previously presented) A process for producing a pharmaceutical composition for treating autoimmune diseases related to a failure of immunoregulation by CD4<sup>+</sup> cells or diminished production of IL-4, comprising mixing autologous or syngeneic T lymphocytes selected from the group consisting of thymocytes, said cells autologous or syngeneic to the patient for whom the composition is intended, said T lymphocytes having previously been incubated in the presence of IL-7 with a pharmaceutically acceptable vehicle or diluent.

12. Canceled

13. (Previously presented) The process for producing a pharmaceutical composition for treating an autoimmune disease according to claim 11, wherein said autoimmune disease is generated by a failure in IL-4 production by T cells with sub-type HSA<sup>-</sup>, CD4<sup>-</sup> CD8<sup>-</sup> or CD4<sup>+</sup>CD8<sup>-</sup>, CD44<sup>+</sup>, TCR- $\alpha\beta^+$ , V $\beta$ 8<sup>+</sup>, NK1.1<sup>+</sup>.

14. (Previously presented) The process for producing a pharmaceutical composition for treating an autoimmune disease according to claim 11, wherein said autoimmune disease is insulin-dependent diabetes mellitus.

15. (Previously presented) The method according to claim 17, wherein a therapeutically effective dose of interleukin-7 is administered to the patient.

16. (Canceled)

17. (Currently amended) A method of treating a patient with an autoimmune disease related to a failure of immunoregulation by CD4<sup>+</sup> cells or diminished production of IL-4 comprising administering to the patient a therapeutically effective dose of interleukin-7 or T lymphocytes selected from the group consisting of thymocytes which have been incubated in the presence of IL-7, said therapeutically effective dose effecting affecting IL-4 production.

18. (Previously presented) The method of claim 17 wherein the treatment comprises a therapeutically effective dose of T lymphocytes which have been incubated in the presence of IL-7.

19. (Previously presented) The method of claim 18 wherein the patient has insulin-dependent diabetes mellitus.

20. (Currently amended) A method of treating a patient with an autoimmune disease expressing an IL-4 deficiency comprising administering to the patient a therapeutically effective dose of T lymphocytes which have been incubated in the presence of IL-7, said therapeutically effective dose effecting affecting IL-4 production.

21. (Previously presented) The method of claim 20, wherein said lymphocytes comprise thymocytes.